Genmab AS SEC Filings

Type
Report
Date
No documents available

Genmab AS Documents 2026

This page contains all official documents and SEC filings for Genmab AS stock (GMAB, ISIN: US3723032062). This includes annual reports (Form 10-K), quarterly reports (Form 10-Q), and insider transactions (Form 4). Currently 0 documents are available. Data is updated regularly to provide investors with a complete overview of Genmab AS's regulatory filings.

Genmab AS Stock analysis

Genmab AS Genmab AS is a biotechnology company based in Copenhagen, Denmark, operating in the Health Care sector. It develops and markets antibody-based therapies for cancer and other diseases, including EPKINLY, TEPKINLY, and Tivdak for various lymphomas and cervical cancer. The company also advances several product candidates in clinical development, such as Epcoritamab for lymphomas and GEN1059 for solid tumors, alongside established treatments like DARZALEX and TECVAYLI for multiple myeloma and other conditions.